Glioblastoma remains one of the deadliest brain cancers, but select academic centers now offer personalized immunotherapy through clinical trial enrollment—treatments tailored to individual tumor biology rather than one-size-fits-all chemotherapy. Eligibility depends on molecular markers, performance status, and post-surgical timing. This guide explains which centers offer these protocols, what criteria determine candidacy, and how evaluation services help navigate trial acce

Glioblastoma remains the most aggressive primary brain tumor in adults, with median survival of 14-16 months under standard care, yet personalized immunotherapy has emerged as a transformative treatment approach achieving significantly improved outcomes at specialized cancer centers. TL;DR Yes, cancer centers including Pi Cancer Care now offer personalized immunotherapy for glioblastoma patients through dendritic cell therapy, CAR-T cell protocols, and tumor-specific vaccine